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ABSTRACT: A miniaturized assay was optimized to evaluate the enhanced apparent water solubility of pyrazolo[3,4-d]pyrimidine 
derivatives used extensively as anticancer drug scaffolds. The applied amount of drugs used in the reported strategy ranged from 5-
10 µg per formulation which were dispensed by an inkjet 2D printer directly into a 96-well plate. The selected polymer/drug formu-
lations with high water solubility demonstrated improved cytotoxicity against a human lung adenocarcinoma cancer cell line 
(A549) compared to the free drugs. We attribute the enhanced efficacy to the improved apparent-solubility of the drug molecules 
achieved via this methodology. This novel miniaturized method showed promising results in terms of water solubility improvement 
of the highly hydrophobic pyrazolo[3,4-d]pyrimidine derivatives, requiring only a few µg of each drug per tested polymeric formu-
lation. In addition, the reported experimental evidence may facilitate identification of suitable polymers for combination with drug 
leading to investigations on biological properties or mechanisms of action in a single formulation.  
The pyrazolo[3,4-d]pyrimidine (p[3,4]p) nucleus (Figure 1(a)) 
is an adenine isostere, and can therefore mimic adenine in the 
catalytic sites of many oncogenic kinases which act on ATP. 
For these reason p[3,4]p has received growing attention as a 
scaffold for the combinatorial synthesis of drug candidates, 
particularly in targeted anticancer therapy based on protein 
kinase inhibitors.
1-5 
Many p[3,4]p derivatives act as nanomolar 
inhibitors of both the cytoplasmic tyrosine kinases SRC, 
ABL1 and FYN,
6,7
 and of the serine-threonine kinase SGK1.
8 
In addition, this family of compounds also showed an en-
hanced antiproliferative profile against several cancer cell 
lines, including those derived from neuroblastoma,
9
 chronic 
myeloid leukaemia,
10 
glioblastoma,
11
 rhabdomyosarcoma,
12 
osteosarcoma,
13
 prostate cancer
14
 and mesothelioma.
15
  
Although these molecules are readily soluble in DMSO and 
other organic solvents, limited solubility in water adversely 
affects their bioavailability and efficacy. Thus, in order to 
avoid the use of toxic organic solvents for in vitro and in vivo 
tests, several strategies have been sought to improve the aque-
ous solubility and pharmacokinetics of p[3,4]p derivatives 
such as formation of complexes with cyclodextrins,
16
 encapsu-
lation into liposomes,
17
 formulation with albumin into nano-
particles
18
 and synthesis of prodrug derivatives.
19 
 
However, one of the simplest and most promising methods is 
to create an amorphous solid dispersion where the drug is mo-
lecularly dispersed in an inert carrier, typically a hydrophilic 
polymer,
20-22
 such that the resulting stabilised amorphous drug 
shows a higher water apparent-solubility compared to the crys-
tal form.
23
  
Accordingly, we have previously developed a novel miniatur-
ized printing technology as a screening method to evaluate 
drug-polymer compatibility.
24
 This new technique represents 
an efficient method to evaluate pharmaceutical formulations 
and assess the compatibility between drug and polymer. It re-
quires only nanogram quantities of materials which results in 
about six orders of magnitude lower amount of active pharma-
ceutical ingredient (API) compared to conventional methods. 
In this regard, routinely analytical techniques such as DSC and 
XRPD need mg of samples to evaluate drug-polymer blends 
stability.   
Here we report, for the first time, an efficient inkjet 2D print-
er-based screening process to identify the best polymeric car-
riers for aqueous solubilisation of different p[3,4]p derivatives 
at minimal sample amounts. We demonstrate a complete min-
iaturized and fast analytical route to determine polymer/drug 
formulations for hit derivatives and validate this approach in a 
standard cytotoxicity screening.  
The initial work involved selection of five previously reported 
p[3,4]p, compounds 1-5
7,15,16,25,26 
(Figure 1SI) and synthesis of 
one new molecule, compound 6.  These candidate drugs were 
combined with seven different commercially available hydro-
philic polymers selected from those commonly used as phar-
maceutical excipients (Figure 1SI). The initial drug and poly-
mer stock solutions were prepared by dissolving the drugs in 
DMSO and the polymers in deionized (DI) water, in order to 
reach a final concentration of 10 mg/mL and 1 mg/mL, respec-
tively. Initially, a fixed volume of each drug solution was dis-
pensed by a piezoelectric printer into a 96-well plate (each 
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 drug was formulated at drug/polymer ratio of 10/90% w/w), 
used as printer target as well as a storage platform. DMSO 
droplets with nominal volumes ranging from 250 to 280 pL 
were dispensed to obtain a final amount of drug of 5-6 µg 
 
 
 
Figure 1.  (a) General structure of pyrazolo[3,4-d] pyrimidines. i. High-throughput dispensing of DMSO drug solutions by inkjet 
2D printer; ii. Sequential addition of polymeric aqueous solutions and evaporation of water and DMSO; iii. Re-suspension with wa-
ter of the dry solid dispersions; iv. Evaluation of the apparent-solubility of the drugs in water from the polymeric matrixes via mul-
ti-well-reader UV-vis analysis; and v. MTT-cytotoxicity assessment of the hit formulations. 
 
 
(Figure 1i). Subsequently (Figure 1ii), the different polymer 
solutions were pipetted into the different wells, by using a pi-
pette (drug controls were prepared by simply adding water ra-
ther than polymer solutions). The well plates were left inside 
the printer cage to allow the DMSO-water mixture to slowly 
evaporate overnight at room temperature (from our previous 
experience
24
, the amount of DMSO dispensed, for each well in 
the present work,
 
evaporates completely in the employed con-
ditions). Subsequently, in order to remove any possible residu-
al trapped solvent in the solid formulations, all the well plates 
were moved into a vacuum drying oven at room temperature 
for two days (Figure 1ii).  
Generally, to dispense the complete set of 6 pure drugs and to 
pipette the 7 polymers in triplicate, the entire process required 
around 40 minutes and around 15-18 µg per drug. The drug-
polymer solid formulations were then analysed for solubility 
by re-suspension in 200 µL of DI water (Figure 1iii). The 
quantitative determination of any UV-vis active molecule pre-
sent in a solution (in this case the aromatic p[3,4]p derivatives) 
can be obtained by comparison with its calibration curve plot-
ted using several solutions of known concentration. However, 
due to the low solubility and stability in water and DMSO re-
spectively of the whole set of drugs, it was not possible to de-
termine quantitatively the amount of soluble component. To 
overcome this problem in a pragmatic manner, an analytic 
screening based on the variation of the absorbance between 
the free drug re-dissolved in water and its polymer formulation 
was developed (Figure 1iv). This was achieved by normalizing 
the absorbance values of the drug/polymer dispersions against 
the absorbance of the free drug in water at the same maximum 
wavelength. The resulting values (∆A%) were then used to 
compare the ability of the different polymers to solubilise the 
sample set of drugs. The absorbance (A0) of the drugs alone in 
water was evaluated by using a UV-vis multi-well plate read-
er, which was able to measure the full wavelength-spectrum in 
the range between 200 to 1000 nm in less than 30 seconds per 
sample. As anticipated, no signals were observed from the 
presence of water-insoluble drugs (Figure 2SI and 3SI). In 
parallel, the absorbance of the aqueous solutions of 
drug/polymer blends (A) was tested by using the absorbance 
of the polymer solutions as a blank (Figure 4SI). All the ab-
sorbance values were kept in the range 0<A<1 where the Beer-
Lambert law can be considered valid and thus, the correlation 
between absorbance and drug concentration. 
 
 
Detailed data of ∆A% values for each polymer/drug combina-
tion can be found in Supporting Information (Table 1SI and 
Figures 5SI-6SI). It is apparent from these data that two sur-
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 factants (Pluronic F-68 and Tween 80) and the amphiphilic co-
polymer PVPVA showed notably higher ∆A% average values 
compared to the homopolymers (PEG 8000-20000, PVP and 
HPMC). Based on these data, ∆A% average values were cal-
culated and used to rank the polymers in terms of drug appar-
ent-solubility enhancement (Figure 2). This was anticipated, 
since as a first assumption, the trend in solubilising hydropho-
bic drugs might be attributed to the presence of hydrophobic 
blocks in Pluronic F-68, Tween 80 and PVPVA, which could 
participate in associative interactions with the drugs. However, 
it is also interesting to highlight that, in this first-generation 
array, PEG chain length also affected the overall drug appar-
ent-solubility (Figure 2), which increased independently from 
the initial water solubility of the drugs (see Figures 3SI).  
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Figure 2. ∆A% average of polymers ranked according to their 
water apparent-solubility enhancement (high ∆A% is related a 
high drug water solubility). Error bars showing standard deviation 
(n=3). 
After this first analytical screening, on the basis of the ∆A% 
average results, each drug was formulated with two of the best 
performing polymers from the initial set i.e. PVPVA, Pluronic 
F-68 and Tween 80 (Table 1SI).  
The anti-proliferative activity of the p[3,4]p derivatives alone 
or in combination with polymers was assessed against a hu-
man lung adenocarcinoma cell line (A549), due to its high cy-
tosolic content of tyrosine and serine-threonine kinases (Fig-
ure 1v). As shown in Figure 3, none of the drugs formulated as 
aqueous suspensions was cytotoxic after 24 h treatment. Be-
fore screening the drug-polymer formulations, all the polymers 
were also tested at varying concentrations against the A549 
cell line (Figure 7SI) to evaluate their cytotoxicity and identify 
the least toxic polymer concentration, in order to avoid any 
effects of the polymer carrier on the final formulation killing 
activity. 
The data showed that the polymers were essentially non-toxic 
to A549 cells up to concentrations of 200 µg/mL. Subsequent 
solid dispersion cytotoxicity assays were therefore performed 
at polymer carrier concentrations below the threshold level of 
200 µg/mL. 
 
Figure 3. Cytotoxicity of pure drug solutions (30 µg/mL) 
against human lung adenocarcinoma cell line (A549). Due to 
the low solubility of the whole set of drugs, no antiprolifera-
tive activity was shown in the high-throughput MTT assay 
adopted. Error bars showing standard deviation (n=4). 
 
Printing of drugs into polymer dispersions at a level of 90% 
polymer and assays of these formulations with A549 cells 
showed growth inhibition of ~ 20-50% (Figure 4), and more 
than the drugs alone at 30 µg/mL. These data also showed that 
compounds 1 and 2 were the most active drug candidates 
(Figure 4). We also used this formulation process to identify a 
pair of drugs to evaluate the combined effect of two more po-
tent active principles in a single polymeric blend, thus 1 (15 
µg/mL) and 2 (15 µg/mL) were formulated with PVPVA 
(drug/polymer ratio constant at 10/90 % w/w). As shown in 
Figure 4 (red bar) a synergistic effect of the combined formu-
lation (1+2-PVPVA) was observed with respect to the single 
ones. In particular, a further 15-20% growth inhibition was 
reached (~60% of killing effect). This experimental evidence 
may both facilitate the future adoption of drug combinations in 
the field of kinase inhibitors and dosage of drugs with differ-
ent nature and/or mechanisms of action in one single formula-
tion. To further validate this methodology, traditional cell via-
bility assays using DMSO drug solutions were also performed 
(Figure 8SI). As can be seen in Figure 8SI, formulations gave 
similar or more accurate cytotoxicity results than that obtained 
with DMSO. These latter results not only support the analyti-
cal evidence of an improved drug water-solubility after formu-
lation but also support the enhancement of availability con-
ferred by solid dispersions. 
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Figure 4. Cytotoxicity of selected pre-screened formulations. 
The final drug concentration reached in the formulations was 
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 around 30 µg/mL equal to a loading in the polymer matrix of 
10% w/w. As shown in Figure, polymers alone showed no ad-
verse activity against the selected cell type.  Red bar: cytotox-
icity of 1+2-PVPVA at 30 µg/mL in drugs (15 µg/mL, 15 
µg/mL of 1+2). Error bars showing standard deviation (n=4). 
 
 
In an attempt to shed some light upon the interactions estab-
lished in between drug and polymer, some preliminary exper-
iments were carried out using Dynamic Light Scattering 
(DLS). This was carried out on just the most powerful single 
drug formulation (1-PVPVA) resulting from the biological 
screening reported in the present work (Figure 4). PVPVA 
showed a poor correlation curve indicating a highly disperse 
preparation, and the resulting DLS traces could be interpreted 
as a mixture of small and large polymer micelles. A similar 
poor correlation curve accompanied with the presence of big 
aggregates were observed for the free form of 1 as would be 
expected from its low solubility (Figure 9SI). On the other 
hand, the 1-PVPVA formulation showed a single unimodal 
peak in the range of 1000 nm with a discrete dispersion (PDI 
of 0.4). As the only peak in this sample this must be a mixture 
of both polymer and drug, hinting at a degree of interaction in 
between the hydrophilic polymeric matrix and the hydropho-
bic drug (Figure 5 and 9SI). The self-assembling of the 1-
PVPVA blend into nano-micro structures might explain not 
only the higher apparent-solubility of the formulation, com-
pared to the free drug, but also the enhanced biological activi-
ty, due to a higher bioavailability than the free drug. This re-
sult provides preliminary support for the effectiveness of the 
new method. However, a more rigorous study would be need-
ed to prove the exact nature of polymer-drug interactions and 
the features of any structure in particles of the final blend.    
 
 
Figure 5. DLS traces in DI water of untreated 1 (red), PVPVA 
(green) and 1-PVPVA (blue) as a formulation. Light scattering 
measurements were collected on suspensions prepared with a 
final concentration of 0.5 mg/mL in drug (concentration 
adopted due to instrumental detection limits).   
 
It is worth remarking that the drugs alone have a really low 
water solubility (Figure 3SI), which reflects the neglectable 
availability in water (Figure 3). While, by formulating the 
p[3,4]p derivatives as reported in the present method, the mol-
ecules become more soluble and can support a concentration 
around 30 µg/mL for the cell assays,.
26
  
In conclusion, in the present work, we have developed a new 
miniaturized screening process, based on an inkjet printing 
technology, able to identify the best formulation to enhance 
the apparent water solubility of some p[3,4]p derivatives, ac-
tive as kinase inhibitors. From the ∆A% as a single value for 
each combination drug/polymer or a ∆A% average value to 
rank the apparent-solubility enhancement, we have identified 
the best polymers able to solubilize the p[3,4]p in water. The 
low quantity of drugs used in the present experiments is one of 
the strongest points of the reported method.  In fact, we have 
used in total less than 20 µg for each drug. This is crucial since 
the synthesis of these molecules encompasses difficult and 
time consuming synthetic steps with long workup procedures 
and high organic solvent consumption. Moreover, with this 
strategy, it is possible to carry out biological tests for these 
drugs without direct drug dissolution in DMSO as required in 
previous work.
27
 This method offers a powerful strategy to 
overcome the problem of the low solubility of this class of 
compounds and/or other systems involving different poorly 
water-soluble drugs. As a consequence, formulations can be 
readily identified for biological (in vitro-in vivo) studies and as 
a starting point for more detailed formulation work.  
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